Vir Biotechnology, Inc. 8-K

What Happened
On January 12, 2026, Vir Biotechnology, Inc. (VIR) filed an 8‑K and issued a press release providing its preliminary cash, cash equivalents and investments balance as of December 31, 2025 (unaudited and subject to adjustment). The company said it expects to report its fourth-quarter and full-year 2025 financial results in late February 2026. Vir also announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026; the presentation slides are being posted on the company’s investor website and will be webcast.

Key Details

• The 8‑K (filed Jan 12, 2026) discloses a preliminary, unaudited cash, cash equivalents and investments balance as of December 31, 2025 (amount not restated in the filing).
• Vir expects to release Q4 and full-year 2025 financial results in late February 2026.
• Presentation scheduled for Jan 14, 2026 at 3:45 p.m. PT at the J.P. Morgan Healthcare Conference; slides attached as Exhibit 99.2 and will be webcast and archived on https://investors.vir.bio for 30 days.
• Exhibits filed: press release dated Jan 12, 2026 (Exhibit 99.1) and investor presentation dated Jan 14, 2026 (Exhibit 99.2). The 8‑K is signed by CEO Marianne De Backer.

Why It Matters
Liquidity disclosures (cash, cash equivalents and investments) give investors an early view of Vir’s financial runway and ability to fund operations before audited results are released. The timing note — Q4 and full‑year 2025 results expected in late February — sets investor expectations for the next material financial update. The J.P. Morgan presentation is a common forum for management to provide business and pipeline updates; slides and the webcast provide another near‑term source of information for assessing strategy and prospects.